{"id":"carboplatin-auc2","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Myelosuppression"},{"rate":"20-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Neuropathy"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Carboplatin is a platinum-based chemotherapy drug that works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.","oneSentence":"Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:12.940Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Breast cancer"},{"name":"Lung cancer"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT02905591","phase":"PHASE2","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph J. Cullen, MD, FACS","startDate":"2018-11-16","conditions":"Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer","enrollment":43},{"nctId":"NCT06493019","phase":"PHASE2","title":"Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer","status":"RECRUITING","sponsor":"Dustin Deming","startDate":"2024-09-30","conditions":"Anal Cancer","enrollment":23},{"nctId":"NCT02359968","phase":"PHASE2","title":"PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02-26","conditions":"Esophageal Neoplasms, Gastro-esophageal Junction Cancer","enrollment":106},{"nctId":"NCT04191135","phase":"PHASE2","title":"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Triple Negative Breast Neoplasms","enrollment":462},{"nctId":"NCT07342283","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-25","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT06099769","phase":"PHASE2","title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-18","conditions":"Metastatic Breast Cancer","enrollment":201},{"nctId":"NCT01345851","phase":"NA","title":"Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2011-03-23","conditions":"Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer","enrollment":29},{"nctId":"NCT04620187","phase":"PHASE2","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-24","conditions":"Salivary Gland Cancer, HER2 Gene Mutation","enrollment":55},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT03579394","phase":"NA","title":"Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2018-10-19","conditions":"Ovarian Cancer Stage IV, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IIIb","enrollment":211},{"nctId":"NCT02525757","phase":"PHASE2","title":"MPDL3280A With Chemoradiation for Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-26","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT06027268","phase":"PHASE2","title":"Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-01-10","conditions":"Metastatic Triple-Negative Breast Cancer","enrollment":36},{"nctId":"NCT04391049","phase":"PHASE1","title":"Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-02","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":16},{"nctId":"NCT07371208","phase":"PHASE2","title":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-12-24","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT07347444","phase":"PHASE2","title":"Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02","conditions":"Acral Melanoma, Mucosal Melanoma","enrollment":48},{"nctId":"NCT07343531","phase":"NA","title":"A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brachytherapy In Cervical Cancer","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-07-01","conditions":"Cervical Carcinoma Stage III, Cervical Carcinoma Stage IIB, Cervical Carcinoma Stage II","enrollment":30},{"nctId":"NCT06466382","phase":"NA","title":"OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy","status":"RECRUITING","sponsor":"Swiss GO Trial Group","startDate":"2025-03-31","conditions":"Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma","enrollment":60},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06416696","phase":"PHASE2","title":"Toripalimab for High-risk Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-09","conditions":"Cervical Cancers","enrollment":57},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT02001272","phase":"PHASE2","title":"EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-12","conditions":"Ovarian Cancer","enrollment":120},{"nctId":"NCT04722978","phase":"PHASE3","title":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2021-04-20","conditions":"Triple Negative Breast Cancer","enrollment":228},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT02297217","phase":"PHASE2","title":"Chemoradiotherapy for Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2019-11-21","conditions":"Esophageal Cancer","enrollment":50},{"nctId":"NCT06735131","phase":"PHASE2","title":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-20","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT06914011","phase":"PHASE3","title":"Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-01-06","conditions":"Esophageal Cancer","enrollment":172},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT07244965","phase":"PHASE2","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-12-01","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":42},{"nctId":"NCT03371017","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-01-11","conditions":"Triple Negative Breast Neoplasms","enrollment":595},{"nctId":"NCT01187199","phase":"PHASE1","title":"Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08-19","conditions":"Advanced Cancer","enrollment":278},{"nctId":"NCT05382286","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-07-25","conditions":"Triple Negative Breast Cancer, PD-L1 Positive","enrollment":443},{"nctId":"NCT01770418","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2013-03","conditions":"Lung Neoplasms","enrollment":32},{"nctId":"NCT02962063","phase":"PHASE1, PHASE2","title":"Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-11","conditions":"Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT05382299","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-07-20","conditions":"Triple Negative Breast Cancer, PD-L1 Negative","enrollment":623},{"nctId":"NCT04555226","phase":"NA","title":"The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2021-01-11","conditions":"Cervical Cancer","enrollment":452},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT07107217","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-08","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT07112833","phase":"PHASE2","title":"A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-08-10","conditions":"Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT07105592","phase":"PHASE1, PHASE2","title":"A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-13","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT06290505","phase":"PHASE2","title":"A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-08","conditions":"Esophageal Cancer","enrollment":54},{"nctId":"NCT02436993","phase":"PHASE2","title":"Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2015-04","conditions":"Breast Carcinoma","enrollment":120},{"nctId":"NCT02455141","phase":"PHASE3","title":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-03","conditions":"Breast Neoplasm","enrollment":786},{"nctId":"NCT06687876","phase":"PHASE2","title":"Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2025-03-09","conditions":"Oesophageal Adenocarcinoma, Tumor Microenvironment","enrollment":14},{"nctId":"NCT04083963","phase":"PHASE2","title":"Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2019-08-09","conditions":"Triple Negative Breast Cancer","enrollment":13},{"nctId":"NCT02755272","phase":"PHASE2","title":"A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2016-05-31","conditions":"Carcinoma Breast Stage IV","enrollment":87},{"nctId":"NCT07047443","phase":"PHASE2","title":"SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-08-01","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT05276310","phase":"PHASE1","title":"A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy","status":"RECRUITING","sponsor":"ImmuneOncia Therapeutics Inc.","startDate":"2022-06-02","conditions":"Advanced Cancer","enrollment":62},{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":79},{"nctId":"NCT01652820","phase":"PHASE2","title":"Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2001-10","conditions":"Non Small-cell Lung Cancer","enrollment":140},{"nctId":"NCT06637163","phase":"PHASE2","title":"Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-10-24","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT03168880","phase":"PHASE3","title":"A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2010-04","conditions":"Triple Negative Breast Cancer","enrollment":720},{"nctId":"NCT04296175","phase":"PHASE3","title":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-03-05","conditions":"Triple-negative Breast Cancer","enrollment":808},{"nctId":"NCT03631784","phase":"PHASE2","title":"A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-19","conditions":"Non-small Cell Lung Cancer","enrollment":216},{"nctId":"NCT06888531","phase":"PHASE2","title":"Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-03-08","conditions":"Esophageal Malignant Neoplasm Primary","enrollment":30},{"nctId":"NCT06870565","phase":"PHASE3","title":"Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03","conditions":"Gastric-type Endocervical Adenocarcinoma, Cervical Cancer","enrollment":238},{"nctId":"NCT05181462","phase":"PHASE1, PHASE2","title":"Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cantargia AB","startDate":"2022-01-11","conditions":"Triple Negative Breast Cancer","enrollment":117},{"nctId":"NCT04460352","phase":"PHASE3","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2020-11-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":1020},{"nctId":"NCT03937362","phase":"","title":"Pre-Surgery If Needed for Oesophageal Cancer","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2019-08-08","conditions":"Esophageal Cancer","enrollment":200},{"nctId":"NCT04230408","phase":"PHASE2","title":"Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers","status":"COMPLETED","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-03-05","conditions":"Lung Neoplasms","enrollment":48},{"nctId":"NCT06775652","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-01-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":254},{"nctId":"NCT01566240","phase":"PHASE3","title":"Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2012-11-08","conditions":"Cervical Cancer","enrollment":500},{"nctId":"NCT02819518","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-07-27","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":882},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":"HER2-negative Breast Cancer, Advanced Breast Cancer","enrollment":252},{"nctId":"NCT05370144","phase":"NA","title":"A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-02-08","conditions":"Esophageal Cancer","enrollment":42},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT06685796","phase":"PHASE2","title":"A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2023-04-12","conditions":"Advanced Triple-Negative Breast Cancer","enrollment":120},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT06510660","phase":"PHASE2","title":"Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-04-11","conditions":"Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers","enrollment":48},{"nctId":"NCT02492867","phase":"NA","title":"A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2016-01-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":49},{"nctId":"NCT04799249","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-05-14","conditions":"TNBC - Triple-Negative Breast Cancer, Breast Cancer","enrollment":194},{"nctId":"NCT04554771","phase":"PHASE2","title":"Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-01-27","conditions":"Esophageal Adenocarcinoma, Oesophageal Adenocarcinoma, Resectable Carcinoma","enrollment":41},{"nctId":"NCT04481256","phase":"NA","title":"TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2020-11-11","conditions":"Carcinoma, Squamous Cell, Oesophageal Cancer","enrollment":49},{"nctId":"NCT03490292","phase":"PHASE1, PHASE2","title":"Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-05-29","conditions":"Resectable Esophageal Cancer, GastroEsophageal Cancer","enrollment":22},{"nctId":"NCT04435197","phase":"PHASE2","title":"Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2020-08-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":143},{"nctId":"NCT06339060","phase":"PHASE3","title":"An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Esophageal Cancer","enrollment":356},{"nctId":"NCT04215003","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2020-01-20","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT06419673","phase":"PHASE2","title":"Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Cervical Cancer","enrollment":240},{"nctId":"NCT06404671","phase":"NA","title":"Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2023-09-15","conditions":"Ovarian Epithelial Cancer","enrollment":250},{"nctId":"NCT02619448","phase":"EARLY_PHASE1","title":"Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT06079931","phase":"PHASE2","title":"The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-12-05","conditions":"Radiation Pneumonitis","enrollment":30},{"nctId":"NCT03595592","phase":"PHASE3","title":"Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Michelangelo","startDate":"2018-09-07","conditions":"Invasive Breast Cancer","enrollment":650},{"nctId":"NCT02620280","phase":"PHASE3","title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2016-04","conditions":"Invasive Ductal Breast Carcinoma","enrollment":278},{"nctId":"NCT01437449","phase":"PHASE2","title":"Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-10","conditions":"Head and Neck Cancer","enrollment":27},{"nctId":"NCT02607202","phase":"PHASE2","title":"A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)","status":"COMPLETED","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2015-03","conditions":"Unknown Primary Tumors","enrollment":57},{"nctId":"NCT02735057","phase":"PHASE1, PHASE2","title":"Chemoradiotherapy in Elderly Patients With Oesophagus Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-04-04","conditions":"Oesophagus Cancer, Elderly Patients","enrollment":54},{"nctId":"NCT06209294","phase":"PHASE2","title":"Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery","status":"RECRUITING","sponsor":"Xiaohua Wu","startDate":"2023-09-01","conditions":"Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery","enrollment":30},{"nctId":"NCT03840902","phase":"PHASE2","title":"M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-16","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT05492123","phase":"PHASE2","title":"Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-08-30","conditions":"Uterine Cervical Neoplasms","enrollment":112},{"nctId":"NCT02916511","phase":"PHASE2","title":"Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2016-09-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT06170697","phase":"PHASE2","title":"Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT03935256","phase":"PHASE2","title":"Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer","status":"UNKNOWN","sponsor":"Loyola University","startDate":"2019-03-05","conditions":"Endometrial Cancer","enrollment":24},{"nctId":"NCT04992780","phase":"PHASE2","title":"Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-25","conditions":"Non Small Cell Lung Cancer Stage","enrollment":50},{"nctId":"NCT03792347","phase":"PHASE1","title":"Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus","status":"COMPLETED","sponsor":"Hecheng Li M.D., Ph.D","startDate":"2019-01-21","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT04308837","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-12-03","conditions":"Gastric Cancer, Stomach Cancer","enrollment":29}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"HYPOKALAEMIA"},{"count":1,"reaction":"KIDNEY INFECTION"},{"count":1,"reaction":"PACKED RED BLOOD CELL TRANSFUSION"},{"count":1,"reaction":"SEPSIS"},{"count":1,"reaction":"URINARY TRACT INFECTION"}],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Carboplatin AUC2","genericName":"Carboplatin AUC2","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription. Used for Ovarian cancer, Breast cancer, Lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}